Skip to search formSkip to main contentSkip to account menu

enrasentan

Known as: (1S,2R,3S)-3-(2-(2-Hydroxyethoxy)-4-Methoxyphenyl)-1-(3,4-(Methylenedioxy)Phenyl)-5-Propoxy-2-Indancarboxylic Acid, (1S,2R,3S)-3-(2-(2-Hydroxyethoxy)-4-methoxyphenyl)-1-(3,4- (methylenedioxy)phenyl)-5-propoxy-2-indancarboxylic acid 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Carboxylic AcidsEndothelin receptor antagonistIndans

Narrower (1)

SB 217242

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
New Frontiers in Clinical Trials Aimed at Improving Outcome Following Traumatic Brain Injury
To date, over 25 clinical trials have been developed to improve outcome by addressing the first two pathologies. None have been… 
2006
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2002
2002
Antihypertensive Treatment With Enrasentan (SB217242) in an Animal Model of Hypertension and Hyperinsulinemia
Enrasentan is an antagonist of endothelin (ET) receptors. Previous studies have shown that antagonism of ET receptors might… 
Review
2002
Review
2002
Gateways to Clinical Trials. June 2002.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2001
2001
Enrasentan Improves Survival, Limits Left Ventricular Remodeling, and Preserves Myocardial Performance in Hypertensive Cardiac Hypertrophy and Dysfunction
Evidence suggests that endothelin receptor antagonists may have therapeutic potential for the chronic treatment of heart failure… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)